Broadwood Capital
New York, NYfiles as BROADWOOD CAPITAL INC
$1.9bn in 6 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 4.1% of the portfolio this quarter.
Value
$1.9bn
Stocks
6
Top 10 share
100.0%
Turnover
4.1%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
- Insight Molecular DiagnosticsIMDX3.9% of the fund+6%
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Ishares TRIWM
- Share
- 7.5%
- Value
- $143m
- Shares
- 474,920
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Monster BeverageMNST | 40.7% | $779m | 8,107,796 | Held |
| Staar SurgicalSTAA | 24.2% | $463m | 16,123,842 | Held |
| Axon EnterpriseAXON | 20.3% | $389m | 693,504 | Held |
| Ishares TRIWM | 7.5% | $143m | 474,920 | Held |
| Insight Molecular DiagnosticsIMDX | 3.9% | $75m | 12,684,884 | +6% |
| Lineage Cell TherapeuticsLCTX | 3.4% | $65m | 49,560,992 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 24.6% since 30 June 2025.
Where the money is
Everyday goods40.7%
Health care31.5%
Industrials20.3%
Other7.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.